Figure 2.
Figure 2. Survival with imatinib mesylate versus interferon-α within Sokal risk groups. (A) Low risk. (B) Intermediate risk. (C) High risk.

Survival with imatinib mesylate versus interferon-α within Sokal risk groups. (A) Low risk. (B) Intermediate risk. (C) High risk.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal